ANXA2, as a Vγ8Vδ3 TCR ligand, is exposed on the membrane under tumour stress, activating Vδ2neg γδ T-cells to mediate immune surveillance [24], suggesting ANXA2 as a potential immunotherapy target. The gene discussed is ANXA2; the disease is neoplasm.